



NUMERAL LTD

(Incorporated in the Republic of Mauritius)
(Registration number: 098177 C1/GBL)
Primary Listing SEM share code: GOLI.N0000
Secondary Listing JSE share code: XII
ISIN: MU0330N00004
("the Company" or "Numeral")

AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 28 FEBRUARY 2025

BACKGROUND

The Company was incorporated on 1 October 2010 as a public company limited by shares under the Mauritian Companies Act and holds a Global Business Licence issued by the Mauritius Financial Services Commission.

Numeral is registered in the Republic of Mauritius and was listed on the Stock Exchange of Mauritius ("SEM") on 7 July 2011. The Company completed a secondary listing on the Alternative Exchange ("AltX") of the Johannesburg Stock Exchange Limited ("the JSE") on 23 November 2016.

During the year under review, the Company recovered its 50% interest in Cryo-Save South Africa Proprietary Limited ("Cryo-Save"), as detailed in the Company's original announcement dated 18 December 2020 wherein the Company (formerly known as Go Life) advised that it had added Cryo-Save to its group of companies. The recovery of the interest was for no consideration. The Company had effective control over the Cryo-Save operations from 1 September 2024.

It is noted that this is the first time in a number of years that the Company is reporting as a group and the prior year's numbers will not be strictly comparable.

The main focus of the group remains on biotechnology, health and pharmaceuticals.

ACQUISITIONS AND DISPOSALS

The following acquisitions and organic growth have been implemented during the financial year of the company and as post balance sheet events:

- A new South African subsidiary, Numeral Financial Services Proprietary Limited ("NFS"), was acquired with effect from 1 March 2024 at no cost to the Company. NFS is a licensed financial services provider, registered as a Category 1 and Category 2 asset manager (FSP 54132), and is also accredited with the National Credit Regulator (NCR CP 21170). While operations were temporarily deferred during the year under review, NFS forms a key component of Numeral's long-term strategy. It is positioned to enable and support future capital raising, fund management, and investment structuring for biotechnology, health, and medical innovation platforms—aligning with the Group's vision to integrate financial and scientific growth across its ecosystem.
- Numeral acquired an additional 1% interest in Cryo-Save on 1 March 2025. This takes Numeral to 51% shareholding in Cryo - Save.
- Numeral acquired an effective 51% shareholding in Longevity Lab Proprietary Limited ("Longevity") with effect from 1 March 2025 through an issue of ordinary shares in Longevity for cash.
- Numeral acquired an effective 40% shareholding in Isopharm Proprietary Limited ("Isopharm") with effect from 15 May 2025 through an issue of ordinary shares in Isopharm for cash.

- Numeral established a new entity named Celerevive Proprietary Limited ("Celerevive") during the 2025 financial year of which it sold 49% to the Celerevive management team on 1 March 2025. Operations commenced in May 2025.
- Numeral has undertaken a consolidation of its SA operating entities under a central SA holding company, named Numeral SA Holdings Proprietary Limited ("NSH"), established on 18 March 2025, which will be effective in the 2026 financial year and which process was underway prior to publishing these financial statements.
- Numeral established Numeral Treasury Solutions Limited on 19 April 2025, to house the Domestic Medium-Term Note ("DMTN") program in preparation for its listing on the Johannesburg Stock Exchange, which will take place in the 2026 financial year.
- Numeral established Qantara Private Capital Proprietary Limited ("Qantara") as a 100% held subsidiary of NFS on 8 April 2025. Qantara established three Shariah compliant, ethically aligned private equity funds namely: the Qantara Income Fund, the Qantara Growth Fund and the Qantara Property Fund, each as *en commandite* partnerships.

There were no further acquisitions or disposals during the period under review.

RELATED PARTIES

There were no transactions with related parties during the period under review that are material to these results.

BASIS OF PREPARATION

These results have been extracted from the audited annual financial statements for the year ended 28 February 2025 and are prepared in accordance with International Financial Reporting Standards (IFRS), the SEM Listings Rules and the JSE Listings Requirements.

The accounting policies adopted in the preparation of the audited annual financial results are in terms of IFRS and are consistent with those applied in the preparation of the audited financial statements for the year ended 29 February 2024.

These results have been prepared under the supervision of Ms Louise Malan and have been audited by Barnes Associates and issued an unqualified report.

SEGMENTAL ANALYSIS

There are no separate segments on which to report with all operations currently being conducted in South Africa.

SUBSEQUENT EVENTS

There were no material subsequent events other than the final step in the regularisation of the business which had been achieved with the issue of a new Global Business Licence (Licence No. GB25101325 – Code: FS-4.1) under section 72(6) of the Financial Services Act.

PROSPECTS

Numeral is dedicated to regrowing its healthcare and biotech business as well as embracing technological and commercial opportunities in the vertical. It will also seek to diversify the Group through strategic acquisitions and pursuing new distribution channels through innovative platforms and strategic partnerships.

At the stage when a strategic acquisition is undertaken, in meeting the requirements, the Company will issue a listing circular, incorporating revised listing particulars, in accordance with the SEM Listings Rules and the JSE Listings Requirements. The information regarding the prospects of the Company included in this paragraph, including any forward-looking information, was not audited or reviewed by the Company's auditors.

GOING CONCERN

The Company has started to show profits and retains the ongoing support of key shareholders.

DIVIDENDS

No dividends were authorised or paid during the period under review.

DIRECTORS

Mr Glenn Henning was appointed to the Board as a Non-Executive Director with effect from 13 March 2025. There were no other changes to the Board of Directors during the year under review.

ANNUAL GENERAL MEETING

The Annual General Meeting for the year ended 2024 was held on Wednesday, 21 August 2024.

AVAILABLE INFORMATION

Copies of the audited Annual Financial Statements for the year ended 28 February 2025 and the statement of direct and indirect interests of each officer of the Company pursuant to Rule 8(2)(m) of the Securities (Disclosure Obligations of Reporting Issuers) Rules 2007, are available free of charge, upon request at the registered office of the Company at Unit 13 Socota Phoenicia, Sayed Hossen Road, Phoenix, Mauritius.

STATEMENT OF FINANCIAL POSITION

The Company has reported as a group for the first time, with comparative information related to the Company only.

USD	Audited Group 28 Feb-25	Audited Company 29 Feb-24
ASSETS		
Non – Current Assets		
Deferred tax	346 460	-
Loan receivables	641 700	-
Property, Plant and Machinery	133 656	-
	1 121 816	-
Current Assets		
Inventory	32 689	-
Loan receivables	524 345	-
Trade and other receivables	895 482	32 000
Cash and Cash Equivalents	212 662	303
	1 665 178	-
TOTAL ASSETS	2 786 994	32 303
EQUITY AND LIABILITIES		
Equity		
Issued capital	7 926 898	7 926 898
Share premium	20 533 459	20 533 459
Accumulated Loss	(27 972 928)	(28 607 321)
Other reserves	(1 443 782)	-
	(956 354)	(146 964)
Non-controlling interest	(1 035 725)	-
Total Equity	(1 992 079)	(146 964)
LIABILITIES		
Non-current liabilities		
Deferred income	225 625	-
Borrowings	3 800 208	-
	4 025 833	-
Current Liabilities		
Trade and other payables	554 771	75 610
Deferred income	19 908	-
Borrowings	171 031	103 657
Income tax liabilities	7 530	-
	753 240	179 267
Total liabilities	4 779 073	179 267
TOTAL EQUITY AND LIABILITIES	2 786 994	32 303

STATEMENT OF COMPREHENSIVE INCOME

USD	Audited Group 12 months ended 28 Feb-25	Audited Company 12 months ended 29 Feb-24
Other income	1 692 555	83 000
Cost of sales	(368 466)	-
Gross profit	1 324 089	83 000
Administrative expenses	(47 874)	(38 806)
Other expenses	(804 248)	(22 763)
Foreign exchange loss	(221 932)	-
Finance income	-	184
Profit before taxation	250 035	21 615
Taxation	(68 101)	-
Profit for the year	181 934	21 615
Other comprehensive income	-	-
Total comprehensive income for the period	181 934	21 615
Net profit attributed to:		
Owners of the parent	1 217 659	21 615
Non-controlling interests	(1 035 725)	-
	181 934	21 615
Total comprehensive income attributed to:		
Owners of the parent	1 217 659	21 615
Non-controlling interests	(1 035 725)	-
	181 934	21 615
Earnings per share based on weighted average shares	0.014	0.002

STATEMENT OF CASH FLOWS

	Audited Group 12 months ended 28 Feb-25	Audited Company 12 months ended 29-Feb-24
USD		
Cash flows (used in)/generated from operating activities		
Profit for the year	250 035	21 615
<i>Adjustment for:</i>		
Depreciation for property, plant and equipment	382 311	
Consolidation adjustments	(2 145 370)	
<i>Changes in working capital</i>		
Inventory	(32 689)	
Other receivables	(895 482)	(32 000)
Other payables	364 327	(6 030)
Cash flows used in operating activities	(2 076 565)	(16 415)
Cash flows (used in) generated from investing activities		
Acquisition of property, plant and machinery	(515 967)	-
Cash flows used in investing activities	(515 967)	-
Cash flows (used in)/from financing activities		
Repayment of loans from group companies	(1 166 045)	(183 061)
Repayment of financial liabilities	-	(52 422)
Proceeds from issue of shares	-	251 898
Proceeds from borrowings	3 971 239	-
Cash flows from financing activities	2 805 194	16 415
Net movement in cash resources	212 359	-
Balance at the start of the year	303	303
Balance at the end of the year	212 662	303

STATEMENT OF CHANGES IN EQUITY

The statement of changes in equity for the group is presented for the first time below:

Figures in US Dollars	Share capital	Share premium	Accumulated loss	Consolidated reserves	Attributed to equity holders of Group	Non-controlling interest	Total equity
Balance at 01 March 2024	7 926 898	20 533 459	(28 154 863)	-	305 494	-	305 494
Profit for the year	-	-	181 934	-	181 934	-	181 934
Other reserves arising on consolidation	-	-	-	(1 443 782)	(1 443 782)	(1 035 725)	(2 479 507)
Other comprehensive income	-	-	-	-	-	-	-
Balance at 28 February 2025	7 926 898	20 533 459	(27 972 928)	(1 443 782)	(956 352)	(1 035 725)	(1 992 077)

RECONCILIATION OF BASIC EARNINGS TO HEADLINE EARNINGS

USD	Audited 12 months 28-Feb-25	Audited 12 months 29-Feb-24
Basic earnings	181 934	21 615
Adjustments:	-	-
Headline earnings	181 934	21 615
Weighted average number of shares	1 242 500 000	1 242 500 000
Basic and diluted loss per share (USD cents)	0.014	0.002
Headline loss per share (USD cents)	0.014	0.002

This communiqué is issued pursuant to SEM Listing Rules 11.3, 12.14 and 12.20 and section 88 of the Securities Act of Mauritius 2005 as well as the JSE Listings Requirements. The Board accepts full responsibility for the accuracy of the information contained in these Financial Statements. The Directors are not aware of any matters or circumstances arising subsequent to the period ended 28 February 2025 that require any additional disclosures or adjustments to the Financial Statements.

Numeral has its primary listing on the SEM and a secondary listing on the Alternative Exchange of the JSE.

For and on behalf of the board

Mauritius

1 July 2025

Executive Directors: Dave van Niekerk Neville Graham	Non-Executive Directors: Mohamed Yusuf Sooklall Dr Aansa Devi Bedacee Glenn Henning
JSE Sponsor: AcaciaCap Advisors Proprietary Limited	Management Company and Company Secretary: LTS Management Services Limited